Skip to content

Study on deep transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder

Clinical efficacy of deep transcranial magnetic stimulation in the treatment of refractory obsessive-compulsive disorder: a double-blind randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093453
Enrollment
Unknown
Registered
2024-12-05
Start date
2023-09-18
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obsessive-compulsive disorder

Interventions

experimental group:dTMS+medicine
control group:Sham stimulation+medicine

Sponsors

Second Xiangya Hospital of CSU
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Between the ages of 16 and 50, right-handed; 2. Meet the diagnostic criteria of obsessive-compulsive disorder, meet YBOCS >=6 points; 3. Patients who regularly took sertraline for 2 months or more and did not respond to drug therapy; 4. Have self-awareness, clear understanding of the content of the study, can complete the entire experiment, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1.The patient has a present or previous history of any of the following conditions: schizophrenia or other psychotic disorder, dementia or any other neurodegenerative disease, alcohol or substance dependence, any mental illness caused by physical illness or drugs; 2.There are contraindications for transcranial magnetic stimulation, such as the presence of metal or electronic instruments in the skull, brain tissue disease, epilepsy, and electroconvulsive therapy in the past 4 weeks. 3.The patient has claustrophobia; 4.Patients are unable to read and understand patient information forms and informed consent forms or patient self-assessment questionnaires; 5.The patient has serious suicidal tendencies; 6.The patient is participating in other clinical trials;

Design outcomes

Primary

MeasureTime frame
OCD symptom;fMRI;fNIRs;

Countries

China

Contacts

Public ContactWeihui Li

Second Xiangya Hospital of CSU

weihui_li@163.com+86 731 85292158

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026